aTyr Pharma, Inc.
aTyr Pharma, Inc. (ATYR) Revenue
Annual & quarterly revenue history · segment & region breakdown
ATYR · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsaTyr Pharma, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 19.15% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2012 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.00B | -19.15% |
| 2024-12-31 | $0.00B | -$0.00B | -33.43% |
| 2023-12-31 | $0.00B | -$0.01B | -96.60% |
| 2022-12-31 | $0.01B | +$0.01B | — |
| 2021-12-31 | $0.00B | -$0.01B | -100.00% |
| 2020-12-31 | $0.01B | +$0.01B | +2377.49% |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income aTyr Pharma, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
aTyr Pharma, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from aTyr Pharma, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ATYR revenue · 4 questionsATYR's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 19.15% year-over-year from $0.00B in FY2025.
▸ Source: FMP · aTyr Pharma, Inc. SEC filings · GAAP · aTyr Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026